George Ng
Chief Executive Officer bij PROCESSA PHARMACEUTICALS, INC.
Vermogen: 40 704 $ op 31-03-2024
Profiel
George K.
Ng is the founder of SCILEX Pharmaceuticals, Inc. (founded in 2012) and IACTA Pharmaceuticals, Inc. (founded in 2016).
He held the title of President-Business at SCILEX Pharmaceuticals, Inc. from 2012 to 2019.
Currently, Mr. Ng is the Chief Executive Officer & Director at Processa Pharmaceuticals, Inc. (since 2023), Director at TuHURA Biosciences, Inc. (since 2020), President, Chief Operations Officer & Director at Calidi Biotherapeutics, Inc. (United States) (since 2019), and Director at Calidi Biotherapeutics, Inc. (since 2023).
He also serves as a Partner at Peng Life Science Ventures (since 2013).
In the past, Mr. Ng held positions as Director at Inflammatory Response Research, Inc. (2019-2020), Director at Virttu Biologics Ltd.
(2017-2019), Director at Immuneoncia Therapeutics, Inc. (2016-2019), Director at Invent Medical Corp.
(2019-2020), Chief Compliance Officer & Head-Legal at Spectrum Pharmaceuticals, Inc. (2007-2010), Senior Vice President & General Counsel at BioDelivery Sciences International, Inc. (2012-2015), Secretary, Chief Legal Officer & Executive VP at Sorrento Therapeutics, Inc. (2015), and President at Pan Asian Lawyers of San Diego.
Mr. Ng received his undergraduate degree from the University of California, Davis and his graduate degree from the University of Notre Dame The Law School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-01-2024 | 10 500 ( 0.61% ) | 24 833 $ | 31-03-2024 | |
| 12-09-2023 | 28 092 ( 0.08% ) | 15 872 $ | 31-03-2024 |
Actieve functies van George Ng
| Bedrijven | Functie | Begin |
|---|---|---|
| PROCESSA PHARMACEUTICALS, INC. | Chief Executive Officer | 08-08-2023 |
| CALIDI BIOTHERAPEUTICS, INC. | Director/Board Member | - |
| Peng Life Science Ventures | Corporate Officer/Principal | 01-09-2013 |
Morphogenesis, Inc.
 Morphogenesis, Inc. BiotechnologyHealth Technology Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL. | Director/Board Member | 01-02-2020 |
IACTA Pharmaceuticals, Inc.
 IACTA Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology IACTA Pharmaceuticals, Inc. develops and commercializes eyecare products. Its products include IC 265, for dry eye, and IC 270, for allergic conjunctivitis. The company was founded by Damon Burrows, William Pedranti, and George K. Ng in 2016 and is headquartered in Irvine, CA. | Founder | 01-01-2016 |
Eerdere bekende functies van George Ng
| Bedrijven | Functie | Einde |
|---|---|---|
Inflammatory Response Research, Inc.
 Inflammatory Response Research, Inc. Pharmaceuticals: MajorHealth Technology Inflammatory Response Research, Inc. develops pharmaceutical products for the treatment of inflammatory disorders and conditions, including the common cold, traumatic brain injury, and acute radiation syndrome. Its product is a combination of levocetirizine (Xyzal) and montelukast (Singulair) at specific dosing for the treatment of the common cold as a ?Behind the Counter? dose pack. The company was founded in 2011 and is headquartered in Santa Barbara, CA. | Director/Board Member | 01-04-2020 |
| Invent Medical Corp. | Director/Board Member | 01-01-2020 |
Virttu Biologics Ltd.
 Virttu Biologics Ltd. Pharmaceuticals: OtherHealth Technology Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom. | Director/Board Member | 01-04-2019 |
SCILEX Pharmaceuticals, Inc.
 SCILEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA. | Founder | 01-04-2019 |
| ░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Opleiding van George Ng
| University of California, Davis | Undergraduate Degree |
| University of Notre Dame The Law School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| PROCESSA PHARMACEUTICALS, INC. | Health Technology |
| CALIDI BIOTHERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 11 |
|---|---|
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
Morphogenesis, Inc.
Morphogenesis, Inc. BiotechnologyHealth Technology Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL. | Health Technology |
Inflammatory Response Research, Inc.
Inflammatory Response Research, Inc. Pharmaceuticals: MajorHealth Technology Inflammatory Response Research, Inc. develops pharmaceutical products for the treatment of inflammatory disorders and conditions, including the common cold, traumatic brain injury, and acute radiation syndrome. Its product is a combination of levocetirizine (Xyzal) and montelukast (Singulair) at specific dosing for the treatment of the common cold as a ?Behind the Counter? dose pack. The company was founded in 2011 and is headquartered in Santa Barbara, CA. | Health Technology |
SCILEX Pharmaceuticals, Inc.
SCILEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA. | Health Technology |
Virttu Biologics Ltd.
Virttu Biologics Ltd. Pharmaceuticals: OtherHealth Technology Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom. | Health Technology |
| Pan Asian Lawyers of San Diego | |
IACTA Pharmaceuticals, Inc.
IACTA Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology IACTA Pharmaceuticals, Inc. develops and commercializes eyecare products. Its products include IC 265, for dry eye, and IC 270, for allergic conjunctivitis. The company was founded by Damon Burrows, William Pedranti, and George K. Ng in 2016 and is headquartered in Irvine, CA. | Health Technology |
Immuneoncia Therapeutics, Inc.
 Immuneoncia Therapeutics, Inc. Medical/Nursing ServicesHealth Services Immuneoncia Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Seongnam-si, South Korea. The South Korean company's mission is to bring safe, effective, and novel immunotherapies to oncology patients worldwide. Immuneoncia's portfolio includes diverse immune checkpoint antibodies. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, Inc., Immuneoncia leverages both companies' expertise in drug development and antibody engineering. The company was founded in 2016, and the CEO is Heung-Tae Kim. | Health Services |
Calidi Biotherapeutics, Inc. (United States)
 Calidi Biotherapeutics, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development of a cell delivery system for oncology treatments. The company was founded by Allan Camaisa and is headquartered in San Diego, CA. | Commercial Services |
| Peng Life Science Ventures | |
| Invent Medical Corp. |
